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Opportunities for a chronic disease outreach program in China.
The comparison of the prevalence of patients on regular dialy-
sis treatment (RDT) in the 3 areas of Greater China (Taiwan,
Hong Kong, and Mainland) with that of the United States and
Japan shows that, unlike Taiwan, in which RDT has a higher
prevalence than in the United States and Japan, in Mainland
China such prevalence is enormously lower. To make the situa-
tion more in line with that of Taiwan, around 2 million patients
would need to be treated in Mainland China, which would be
a tremendous financial burden. Prevention is the only way to
improve the situation. Preliminary information regarding an
epidemiologic study on the population of Zhuhai, a town in
Southeast China, planned in collaboration with the Commis-
sion for the Global Advancement of Nephrology of the Inter-
national Society of Nephrology and the 5th Affiliated Hospital
of the Sun-Yat-Sen University in Zhuhai, is given here.
Despite certain advances, there are parts of the world
that are completely underdeveloped or still develop-
ing. Obviously, the strategy of the Commission for the
Global Advancement of Nephrology (COMGAN) must
be different in the organization of programs dealing with
nations at different stages of development. In those coun-
tries that have already started the process of economic
development, some valid sanitary structures may already
exist, at least in major cities, and can be of enormous value
in helping efforts of the commission, supporting training
and research, representing a possible link with the health
central authority, and offering a local basis for population
studies and prevention programs.
Greater China, an immense territory of 9.6 million sq
km that includes Mainland China, Hong Kong, and Tai-
wan, serves as model of a rapidly developing geographic
area, where efficient university hospitals and research
institutes exist in some major cities, especially in Be-
jing, Shanghai, and in some Southern Provinces, includ-
ing Chengdu in the Sichuan Province, Guangzhou in the
Guangdong Province, and Hong Kong. However, large
rural areas or entire provinces are still radically underde-
veloped, with an average income of the population being
one third of that of the inhabitants of urban areas.
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Figure 1 summarizes the prevalence of patients on a
regular dialysis program at the end of 2002 in the 3 major
areas of Greater China and, for comparison, the preva-
lence of 2 developed countries, the United States and
Japan. This graph demonstrates how completely differ-
ent the situation is in the various areas of China: the
island of Taiwan, an independent country of 22 million
inhabitants that was constructed in response and in re-
jection of the Communist government on the Mainland;
Hong Kong, a very small territory that houses 7 million
inhabitants, which developed as a British colony, was re-
cently returned to China, and enjoys an almost complete
administrative independence; and Mainland China, with
1.3 billion inhabitants, still a Communist-ruled country
trying to incorporate aspects of the capitalistic system,
which boasts an exceptional annual increase in the gross
domestic product of 10% per year nationally and more
than 20% per year in the industrialized Province of Guan-
dong, on the South China Sea, neighboring Hong Kong
and Macao.
Taiwan has a prevalence of patients reaching 1550 per
million population (pmp), even higher than that of the
United States; this result has been possible because the
cost of routine dialysis therapy is covered completely
by a socialized health insurance program. The situation
in Hong Kong, with a prevalence of 550 patients pmp,
averages between that of Taiwan and Mainland China,
because of the fact that only 60% of inhabitants have
complete coverage treatment costs in public hospitals;
peritoneal dialysis is the modality of treatment for 77%
of patients on dialysis. The situation in Mainland China
is perhaps the most shocking. Despite the overwhelming
numbers of the Chinese population, the total number of
treated patients is only slightly greater than that of Tai-
wan (39,000 vs. 34,000 at the end of 2002), with a total
prevalence that is extraordinarily low, around 30 pmp. A
very simple explanation can be offered: working people
in China have only partial coverage of treatment costs
(with the percentage varying in different provinces), and
unemployed people and those with low incomes have no
coverage at all, with only a few exceptions. In this country,
patients who are not particularly wealthy and have end-
stage renal failure die, unless they work in institutions or
companies that provide special medical insurances.
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Fig. 1. Prevalence of pmp on regular dialy-
sis treatment at the end of 2002 in the 3 ma-
jor areas of Greater China, the United States,
and Japan. Data for the United States and
Japan are official data of the United States
Renal Data System (http://www.USRDS.org/
2003/pdf/12 intl 03.pdf). Data for Taiwan,
Hong Kong, and mainland China have been
kindly provided by Fresenius Medical Care
Asia Pacific.
In my opinion, this situation is the consequence of a
very precise decision by the central government, because
the health care policy in China is strictly planned at the
government level and has obtained very good results in
other fields. If this is the case, it is unrealistic to think
that this lack of support for the expense of dialysis treat-
ment will be corrected by the government, at least in the
next few years. We must realize that a full dialysis treat-
ment program in mainland China, similar to those that
exist in Taiwan, assuming a comparable prevalence of
end-stage renal failure (because the genetic background
is identical), would imply that regular dialysis treatment
should be made available to more than 2 million pa-
tients; this would cost the central government US $100
billion per year. The number of patients that should be
treated in mainland China alone is double that of the to-
tal number of patients being treated now in the entire
world.
The only alternative way to help patients with renal
disease, cardiovascular disease, and diabetes in mainland
China is to prevent the occurrence of the illness itself and
provide good care and surveillance during the early stages
of such diseases. The mission of COMGAN in China must
be to help nephrologists working in facilities of univer-
sity hospitals and sensitize and educate government and
provincial health administrators, so that they might or-
ganize programs in a more efficient manner. In addition,
COMGAN could run long-term pilot screening and in-
tervention programs on sufficiently large populations in
specific geographic areas, according to guidelines already
established by the COMGAN research subcommittee. I
want to emphasize that, even if we should restrict our
interest to screen the potential population with some de-
gree of impairment of renal function, assuming that it
amounts as in the United States to approximately 10%
of the total population, we should correctly treat 130 mil-
lion patients.
The fact that I am here today to give you advanced
notice about a project of pilot population screening and
prevention program in China is due to a favorable series
of chance events. In the past 20 years, in the Division of
Nephrology of the San Carlo Hospital in Milan, we have
accepted as trainees, during different periods, 5 young
Chinese nephrologists. At the end of 1 to 2 years of train-
ing, one of these doctors remained in my unit in Milan
(and I am proud to name her as one of my best collab-
orators), 2 have migrated to the United States, and the
other 2, both fellows of the ISN, returned to China. A
few years after his return to China, one of these doctors,
Professor Hequn Zou, who spent 2 years (March 1995 to
March 1997) in Milan, was appointed as the Head of the
Division of Nephrology in an efficient 1200-bed hospi-
tal that is affiliated with the Sun Yat-Sen University (the
major university of the Guandong Province). This hospi-
tal was recently built in the new town of Zhuhai (with a
population of 1 million), adjacent to Macao, which is a
1-hour boat ride from Hong Kong, on the South China
Gold Coast in the well-known, largely autonomous Spe-
cial Economic Zone. Zhuhai is developing rapidly on the
Southern border of China and should become an alter-
native to Hong Kong as a bridge for fostering economic
exchanges between the People’s Republic of China and
the world.
Six months ago, Professor Zou became the President
of this hospital. He invited me to visit him and discuss
the possibilities of future collaboration with his staff and
asked again for the help of the Department of Nephrol-
ogy and Immunology of the San Carlo Hospital in Milan
for training his young collaborators. We accepted, and
2 members of our staff, including the Chinese doctor
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working with us, moved to Zhuhai for a week and selected
the 2 fellows who would begin their training in Italy in a
few months. We are now joining the Sister Center Pro-
gram of the ISN and are hoping for some financial contri-
butions. Until this point, the Department of Nephrology
at San Carlo had provided for expenses with the help of
the Associazione per la Ricerca in Nefrologia, an associ-
ation I founded many years ago to support the research
in our department.
During my visit to Zhuhai, we also decided to join pro-
grams of prevention organized by the Research Subcom-
mittee of the COMGAN, taking advantage of the role
of Professor Zou as President of his hospital and of the
support of the Sun Yat-Sen University (operating in the
entirety of the Cantonese Province with 8 affiliated hos-
pitals, 7 of which are in Guanzhou). A population study
on thousands, carried out in the area of Zhuhai, could
give highly valid information about the prevalence of
many chronic diseases, besides renal diseases (arterial hy-
pertension, diabetes, cardiovascular events) that, to our
knowledge, is not yet available in mainland China. More-
over, if initial screening would include new early markers
of increased risk for the occurrence of all the abovemen-
tioned diseases (microalbuminuria and C-reactive pro-
tein), of which we have discussed in this supplement, we
will be in the condition to test their validity in the sub-
sequent observational stage of the study and establish
relevant interventional approaches on large numbers of
individuals at risk.
One of the 2 fellows coming to Italy will stay in Berg-
amo, and will be specifically trained to run epidemiologic
studies and prevention programs in the Institute of Dr.
Remuzzi.
Next year, we should be ready to start the experiment in
China. Will we succeed? I am optimistic, and I promise to
provide all the help that I have at my disposal. A success
would demonstrate the correctness and efficaciousness
of the COMGAN strategy. A young Chinese doctor who
had been trained abroad with a grant by the ISN some
years ago could return to China and, with further help
of the ISN, could contribute actively to the program of
development of nephrology in his home country.
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